{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T21:17:56Z","timestamp":1788556676757,"version":"build-2803163510"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T00:00:00Z","timestamp":1733443200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:p>Methamphetamine (MA) dependence leads to severe physical and psychological issues. Current treatments, including psychosocial therapies and residential rehabilitation, face limitations such as high relapse rates, cost, and accessibility issues. As a result, there is an urgent need for novel approaches to treat MA dependence that are effective, affordable, and accessible to patients. Psilocybin, the active component in numerous mushrooms of the <jats:italic>Psilocybe<\/jats:italic> genus, has shown potential for enhancing psychotherapy for various addiction and mental health issues due to its effects on perception, cognition, and affect. Psilocybin-assisted psychotherapy (PAT) has demonstrated initial safety and efficacy in treating alcohol, cocaine, and nicotine dependence. The case presented here describes a 36-year-old transwoman and daily MA user, who participated in a single-arm open-label clinical trial assessing feasibility and safety of PAT for MA dependence at St. Vincent\u2019s Hospital, Sydney. Following inpatient withdrawal management and one session of psilocybin-assisted therapy, she experienced significant cognitive and emotional shifts and sustained MA abstinence. She reported improved mental health over 3 months following treatment completion. She also noted increased self-esteem, mindfulness, and distress tolerance. This study suggests that PAT (following inpatient MA withdrawal management) may offer a scalable, safe, and effective approach for treating MA dependence. However, further research is required to confirm the generalisability and efficacy of PAT for broader populations of people using MA. It is encouraging that this participant, a daily MA user, showed improvements in mood and cognition, in addition to abstinence from MA.<\/jats:p>","DOI":"10.3389\/fpsyt.2024.1490907","type":"journal-article","created":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T06:51:27Z","timestamp":1733467887000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Psilocybin-assisted psychotherapy for methamphetamine dependence: a case report involving daily methamphetamine use"],"prefix":"10.3389","volume":"15","author":[{"given":"Jonathan","family":"Brett","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Knock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy","family":"Watson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Albert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krista J.","family":"Siefried","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Guss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,12,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32230-5","article-title":"Responding to global stimulant use: challenges and opportunities","volume":"394","author":"Farrell","year":"2019","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1177\/1057567717730104","article-title":"Global methamphetamine trends: an evolving problem","volume":"28","author":"Stoneberg","year":"2018","journal-title":"Int Criminal Justice Rev"},{"key":"B3","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.drugalcdep.2006.04.007","article-title":"The relationship between crystalline methamphetamine use and methamphetamine dependence","volume":"85","author":"McKetin","year":"2006","journal-title":"Drug Alcohol Depend"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3109\/16066359.2011.552816","article-title":"Levels of methamphetamine use and addiction among gay, bisexual, and other men who have sex with men","volume":"20","author":"Solomon","year":"2012","journal-title":"Addict Res Theory"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/dar.2017.36.issue-4","article-title":"Critical considerations in responding to crystal methamphetamine use in Australian Aboriginal communities","volume":"36","author":"MacLean","year":"2017","journal-title":"Drug Alcohol Rev"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40263-020-00711-x","article-title":"Pharmacological treatment of methamphetamine\/amphetamine dependence: A systematic review","volume":"4","author":"Siefried","year":"2020","journal-title":"CNS Drugs"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1111\/j.1360-0443.2012.03933.x","article-title":"Evaluating the impact of community-based treatment options on methamphetamine use: findings from the M ethamphetamine T reatment E valuation S tudy (MATES)","volume":"107","author":"McKetin","year":"2012","journal-title":"Addiction"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011866.pub3","article-title":"Psychosocial interventions for stimulant use disorder","volume":"2","author":"Minozzi","year":"2024","journal-title":"Cochrane Database Systematic Rev"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.31128\/AJGP-07-20-5550","article-title":"Qualitative understandings of access to primary care services for consumers who use methamphetamine","volume":"50","author":"Ward","year":"2021","journal-title":"Aust J Gen Pract"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ps.201700242","article-title":"Implementation of contingency management at a large VA addiction treatment center","volume":"68","author":"Ruan","year":"2017","journal-title":"Psychiatr Serv"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2018.05.012","article-title":"The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act","volume":"142","author":"Johnson","year":"2018","journal-title":"Neuropharmacology"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14740338.2022.2047929","article-title":"The therapeutic potential of psilocybin: a systematic review","author":"van Amsterdam","year":"2022","journal-title":"Expert Opin Drug Saf"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2022.2096","article-title":"Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: A randomized clinical trial","volume":"79","author":"Bogenschutz","year":"2022","journal-title":"JAMA Psychiatry"},{"key":"B14","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3109\/00952990.2016.1170135","article-title":"Long-term follow-up of psilocybin-facilitated smoking cessation","volume":"43","author":"Johnson","year":"2017","journal-title":"Am J Drug Alcohol Abuse"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2023.1123424","article-title":"Exploring psilocybin-assisted psychotherapy in the treatment of methamphetamine use disorder","volume":"14","author":"Brett","year":"2023","journal-title":"Front Psychiatry"},{"key":"B16","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1046\/j.1440-1614.1999.00517.x","article-title":"Amphetamine withdrawal: I. Reliability, validity and factor structure of a measure","volume":"33","author":"Srisurapanont","year":"1999","journal-title":"Aust New Z J Psychiatry"},{"key":"B17","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1037\/a0030992","article-title":"Reliability of the Timeline Followback for cocaine, cannabis, and cigarette use","volume":"28","author":"Robinson","year":"2014","journal-title":"Psychol Addictive Behav"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/jclp.2012.68.issue-12","article-title":"The depression anxiety stress Scales\u201421 (DASS-21): further examination of dimensions, scale reliability, and correlates","volume":"68","author":"Osman","year":"2012","journal-title":"J Clin Psychol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1477-7525-5-63","article-title":"The Warwick-Edinburgh mental well-being scale (WEMWBS): development and UK validation","volume":"5","author":"Tennant","year":"2007","journal-title":"Health Qual Life Outcomes"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1177\/0269881115609019","article-title":"Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin","volume":"29","author":"Barrett","year":"2015","journal-title":"J Psychopharmacol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1177\/0269881119855974","article-title":"Emotional breakthrough and psychedelics: Validation of the Emotional Breakthrough Inventory","volume":"33","author":"Roseman","year":"2019","journal-title":"J Psychopharmacol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1080\/02791072.2021.1957183","article-title":"Psychedelic knowledge and opinions in psychiatrists at two professional conferences: an exploratory survey","volume":"54","author":"Barnett","year":"2022","journal-title":"J Psychoactive Drugs"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/ajad.13461","article-title":"Addiction specialists' attitudes toward psychedelics: A National Survey","volume":"32","author":"Kim","year":"2023","journal-title":"Am J Addict"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2023.1134454","article-title":"Therapeutic effect of psilocybin in addiction: A systematic review","volume":"14","author":"van der Meer","year":"2023","journal-title":"Front Psychiatry"},{"key":"B25","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/dar.13511","article-title":"Pharmacological treatment for methamphetamine withdrawal: A systematic review and meta-analysis of randomised controlled trials","volume":"42","author":"Acheson","year":"2023","journal-title":"Drug Alcohol Rev"},{"key":"B26","article-title":"National drug strategy household survey 2022-23","year":"2024"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2024.1490907\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T06:51:29Z","timestamp":1733467889000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2024.1490907\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,6]]},"references-count":26,"alternative-id":["10.3389\/fpsyt.2024.1490907"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2024.1490907","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,6]]},"article-number":"1490907"}}